Diabetes (Type 1 & 2) treatment options (2026): standard, alternative & regenerative
Type 1 diabetes involves autoimmune loss of insulin-producing beta cells; Type 2 diabetes involves heterogeneous combinations of insulin resistance and beta-cell dysfunction. Research includes stem-cell-derived islets, donor islets, encapsulation, gene editing and immune modulation, but these are distinct technologies with different risks and regulatory status. A generic MSC infusion should not be equated with replacement of functional pancreatic islets.
Standard & first-line treatment for Diabetes (Type 1 & 2)
Established care should follow a diagnosis-specific plan made with a suitably qualified clinician. Depending on the condition, that plan may include cause-directed treatment, authorised medicines or procedures, rehabilitation, monitoring and supportive care. Selection depends on severity, other illnesses, current medicines, contraindications and the person's goals. An experimental product must not displace urgent or time-sensitive established care.
Alternative & complementary options
Complementary approaches are not interchangeable with established treatment. Evidence, product quality, interactions and practitioner regulation differ by method and condition. Ask what outcome was studied, in which population, against which comparator and for how long. Discuss supplements, devices and procedures with the treating team, and do not use testimonials or a package label as evidence of benefit.
Regenerative and cell interventions: evidence and regulatory status
FDA-approved Lantidra (donislecel-jujn) is an allogeneic pancreatic-islet cellular therapy made from deceased-donor pancreatic cells for a narrow group of adults with Type 1 diabetes and recurrent severe hypoglycaemia despite intensive management. It is infused into the hepatic portal vein and requires concomitant immunosuppression; it is not a general stem-cell cure for Type 1 or Type 2 diabetes. See the FDA Lantidra record and the NIDDK islet-transplant overview. Treat this as product-specific research, not as a generic treatment class. Verify the exact product, source, processing, manufacturer, dose, route, indication, regulator or ethics approval, comparator, endpoints and adverse-event plan. See the condition evidence page for registry and study context.
Diabetes (Type 1 & 2) treatment options compared
| Option | Type | Evidence | Cost information | Invasiveness | Recovery |
|---|---|---|---|---|---|
| Diagnostic and specialist assessment | Standard | Required to define diagnosis, cause, severity and suitability | Varies by tests, country, coverage and provider; request an itemised quote | Depends on the assessment | No universal timeline |
| Guideline-directed established care | Standard | Condition- and patient-specific; use the current clinical guideline | Varies by treatment, country and coverage; request an itemised quote | Depends on the selected treatment | Defined by the selected established treatment |
| Rehabilitation, monitoring and supportive care | Standard / supportive | Condition- and goal-specific | Varies by programme, duration, country and coverage | Usually low, but programme-specific | Ongoing and goal-specific |
| Cell, exosome or other regenerative intervention | Authorised clinical trial only / research | Investigational; exact product and indication must be verified | A commercial price is not evidence of approval, safety or efficacy | Depends on collection, processing and administration | Defined by the authorised protocol; benefit is uncertain |
Diabetes (Type 1 & 2) treatment — common questions
How should established options be selected?
Start with a confirmed diagnosis and an independent clinician who can apply the current condition-specific guideline. Compare expected benefits, harms, burden, alternatives and what happens without treatment. Choice cannot be reduced to a universal ranking or a commercial package.
Is a regenerative product approved for this condition?
Lantidra is FDA-approved for a narrow adult Type 1 diabetes indication; it is donor pancreatic-islet cellular therapy, not a generic stem-cell infusion. This approval does not extend to Type 2 diabetes, MSC products, exosomes or another manufacturer's preparation.
How should cost and value be assessed?
Costs cannot be generalised across routine diabetes care, authorised islet transplantation and investigational cell products. Obtain an itemised estimate for assessment, product, procedure, immunosuppression where applicable, monitoring, travel and complication care. Do not interrupt insulin or other established treatment because an experimental programme is being considered. Coverage depends on product, indication, country and policy. Obtain a written eligibility and coverage decision for the exact authorised treatment or trial, including immunosuppression, monitoring and complications; do not infer it from coverage of insulin. The answer depends on the exact authorised indication or research protocol, not the label cell therapy. A specialist independent of the seller should compare established diabetes technology and medicines, transplant options where relevant, protocol risks and total burden.
Sources & further reading
We link primary regulators, registries and peer-reviewed research so you can verify everything yourself — plus the treating clinic's own materials.
- Open clinical trials for Diabetes (Type 1 & 2) (ClinicalTrials.gov) ↗
- Peer-reviewed research on PubMed ↗
- ISSCR patient guide — what to ask ↗
- FDA consumer warning on stem-cell therapies ↗
- EMA — advanced-therapy (ATMP) framework ↗
- Clinic perspective — Stem Plus on Diabetes (Type 1 & 2) ↗
Educational overview only; not medical advice. Verify current guidance, regulatory status and treatment options with the cited authorities and an independent qualified physician.
More on this condition
- Diabetes (Type 1 & 2): cell-therapy evidence and registered trials
- How much does stem cell therapy for Diabetes (Type 1 & 2) cost? (2026)
- Diabetes (Type 1 & 2) stem cell therapy — your questions answered (2026)
- Diabetes (Type 1 & 2): cell-therapy evidence by therapy class
- MSC vs HSCT for Diabetes (Type 1 & 2): what the registries show